In another study, NSCLC patients treated with pembrolizumab showed objective response rate (ORR) of 45.2% if ≥50% of the tumor cells were PD-L1-positive on immunohistochemistry (IHC), whereas only 16.5% of patients responded to treatment if 1–49% of the tumor cells were PD-L1-positive10. This evidence concerns the gene CD274 and non-small cell lung carcinoma.